Hoffmann-la Roche Inc.

Roche Palo Alto LLC

F. Hoffmann-la Roche Ag

Stephen Deems Gabriel

Buelent Kocer

Elbert Chin

Eric Mertz

Steven Joseph Berthel

Zhi Chen

Yan Lou

Andrew William Thomas

Jean-Marc Plancher

Matthew C Lucas

Shawn David Erickson

Francisco Javier Lopez-Tapia

Timothy D Owens

Fariborz Firooznia

Peter Michael Wovkulich

Roland Joseph Billedeau

Christine E Brotherton-Pleiss

David Mark Rotstein

Saul Jaime-Figueroa

Robert James Weikert

Jenny Tan

Xiaochun Han

Lucja Orzechowski

Ramona Hilgenkamp

Feng Chi

Roland Jakob-Roetne

Yimin Qian

Matthew Michael Hamilton

Bernd Buettelmann

Achyutharao Sidduri

Qingjie Ding

Paul Spurr

Jing Zhang

Pius Waldmeier

Nan Jiang

Qiang Zhang

Steven Paul Hanlon

Joseph Anthony Bilotta

David Shawn Erickson

Han Ma

Robert J Weikert

Klaus Klumpp

The present invention discloses compounds of Formula I wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection. 

Antiviral compounds

The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection. 

The present invention discloses compounds of Formula (I): wherein the variables in Formula (I) are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula (I) in the prevention or treatment of HCV infection. 

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of inflammatory diseases and disorders such as, for example, pulmonary fibrosis.

N-alkyltriazole compounds as LPAR antagonists

This application discloses 6-(2-Hydroxymethyl-phenyl)-2-methyl-2H-pyridazin-3-one derivatives according to generic Formula I: wherein, variables X, R, and Y, are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation, such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.

Inhibitors of bruton's tyrosine kinase

The present invention is concerned with novel triazole compounds of formula (I) wherein A, X, Y, u, v, R, R, and Rare as described herein, as well as pharmaceutically acceptable salts thereof. The compounds of present invention have affinity and selectivity for the GABA A &#x3b1;5 receptor. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as pharmaceuticals.

Triazole compounds II

The present invention is concerned with novel hydroxy-methyl isoxazole derivatives of formula I wherein R, Rand Rare as described herein, as well as pharmaceutically acceptable salts and esters thereof. The active compounds of the present invention have affinity and selectivity for GABA A &#x3b1;5 receptor. Further the present invention is concerned with the manufacture of the active compounds of formula I, pharmaceutical compositions containing them and their use as pharmaceuticals.

Substituted isoxazoles

This invention relates to piperidine derivatives of formulae Ia and Ib with substituents as defined herein useful in the treatment of a variety of disorders, including those in which the modulation of CCR5 receptors is implicated. More particularly, the present invention relates to 1-oxa-3,8-diaza-spiro[4.5]decan-2-one and 1-oxa-3,9-diaza-spiro[5.5]undecan-2-one compounds and related derivatives, to compositions containing and to uses of such derivatives. Disorders that may be treated or prevented by the present derivatives include HIV and genetically related retroviral infections (and the resulting acquired immune deficiency syndrome, AIDS), diseases of the immune system and inflammatory diseases. 

Heterocyclic antiviral compounds

Growing community of inventors

Morristown, NJ, United States of America

Stephen Deems Gabriel